Clincosm LogoSign in Get a demo

Vasoactive Peptides in Portal Pressure

Sponsor
Bayside Health (Other)
Overall Status
Unknown status
CT.gov ID
NCT00163982
Collaborator
(none)
1
Location

Study Details

Study Description

Brief Summary

This study is looking at the detection of vasoactive peptides in portal hypertension.

Condition or Disease Intervention/Treatment Phase
N/A

Study Design

Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Double
Primary Purpose:
Treatment

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • HVPG >= 12 mmHg

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Alfred Hospital Melbourne Victoria Australia 3181

    Sponsors and Collaborators

    • Bayside Health

    Investigators

    • Principal Investigator: William W Kemp, MBBS, FRACP, The Alfred

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00163982
    Other Study ID Numbers:
    • AH4204
    First Posted:
    Sep 14, 2005
    Last Update Posted:
    Jul 26, 2007
    Last Verified:
    Sep 1, 2005
    Keywords provided by , ,
    HVPG > 12 mmHg
    Additional relevant MeSH terms:
    Hypertension, Portal
    Norfloxacin

    Study Results

    No Results Posted as of Jul 26, 2007